Product Description
Antipodean's lead compound Mitoquinone (MitoQ®) is a potent, orally active compound that assists with mitochondrial oxidative damage and supports cell health. (Sourced from: https://www.antipodeanpharma.com/our-team)
Mechanisms of Action: HIF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Antipodean
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Kidney Failure, Chronic|Healthy Volunteers|Generalized anxiety disorder
Phase 3: Schizophrenia|Mitochondrial Diseases
Phase 2: Inflammation|Parkinson's Disease|Dementia|Cognitive Dysfunction|Colitis, Ulcerative|Multiple Sclerosis|Lower Urinary Tract Symptoms|Overactive Bladder|COVID-19|Cardiomyopathies|Severe Acute Respiratory Syndrome|Cardiomyopathy, Dilated|Non-alcoholic Fatty Liver Disease|Carotid Artery Diseases|Aortic Diseases|Fatty Liver, Alcoholic|Mitochondrial Diseases|Oxidative Stress|Liver Diseases, Alcoholic|Hepatitis A|Hepatitis C, Chronic
Phase 1: Menopause|Chronic Obstructive Pulmonary Disease|Asthma|Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| F3810-R | N/A |
Recruiting |
Post Acute COVID-19 Syndrome |
2027-10-31 |
|
| MOVHS | N/A |
Recruiting |
Hypertension |
2026-08-31 |
|
| 2024P000030 | P3 |
Not yet recruiting |
Mitochondrial Diseases|Schizophrenia |
2027-01-31 |
|
| 0053-23-EP | N/A |
Recruiting |
Peripheral Vascular Diseases|Peripheral Arterial Disease |
2026-10-30 |